El papel de la vacuna SARS-CoV-2 en población con trasplante hepático

Chávez-García, Luis Carlos; Juárez-León, Oscar; Barreda-Mecalco, Eduardo; Baeza-Zapata, Armando; García-Juárez, Ignacio.
Salud pública Méx ; 63(5): 588-588, sep.-oct. 2021. tab
Artículo en Español | LILACS-Express | ID: biblio-1432296

Documentos relacionados

  1. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase.
  2. Hierarchical Vaccine Allocation Based on Epidemiological and Behavioral Considerations.
  3. Prevalence of risk behaviors and correlates of SARS-CoV-2 positivity among in-school contacts of confirmed cases in a Georgia school district in the pre-vaccine era, December 2020-January 2021.
  4. Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8<sup>+</sup> T cell responses post SARS-CoV-2 infection.
  5. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases.
  6. Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination.
  7. Does natural and hybrid immunity obviate the need for frequent vaccine boosters against SARS-CoV-2 in the endemic phase?
  8. What makes SARS-CoV-2 unique? Focusing on the spike protein.
  9. Omicron's message on vaccines: Boosting begets breadth.
  10. Of variants and vaccines.